Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study

Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study

Pokaż inne wersje (1)

The reported higher risk of maternal and fetal complications in women with myeloproliferative neoplasms (MPN) poses challenge during pregnancy. A national prospective study of maternal and fetal outcomes of pregnant women with a diagnosis of MPN was undertaken via the United Kingdom Obstetric Survei...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Alimam, S, Bewley, S, Chappell, L, Knight, M, Seed, P, Gray, G, Harrison, C, Robinson, S
Format:	Journal article
Wydane:	John Wiley & Sons Ltd 2016

Podobne zapisy

Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study.
od: Alimam, S, i wsp.
Wydane: (2016)

Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms
od: Dawn Maze, i wsp.
Wydane: (2023-02-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
od: Butt, N, i wsp.
Wydane: (2019)

Myeloproliferative neoplasms
od: Nick Cross, (Coordinating Author)
Wydane: (2019-06-01)

Myeloproliferative neoplasms
od: Jean-Jacques Kiladjian
Wydane: (2018-06-01)

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms
od: Luca Malcovati, i wsp.
Wydane: (2014-11-01)

S199: A NATIONAL RETROSPECTIVE COHORT STUDY OF MPN-SVT: RESULTS FROM THE UK MYELOPROLIFERATIVE NEOPLASMS ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (MASCOT) REGISTRY
od: R. Hargreaves, i wsp.
Wydane: (2022-06-01)

Are we ready for disease modification in myeloproliferative neoplasms?
od: Claire N. Harrison
Wydane: (2024-09-01)

Bone marrow niche dysregulation in myeloproliferative neoplasms
od: Natalia Curto-Garcia, i wsp.
Wydane: (2020-05-01)

The microenvironment in myeloproliferative neoplasm
od: Simón Méndez-Ferrer, i wsp.
Wydane: (2018-06-01)

Spleen in myeloproliferative neoplasms
od: Giovanni Barosi
Wydane: (2018-06-01)

Epigenetics in myeloproliferative neoplasms
od: Graeme Greenfield, i wsp.
Wydane: (2023-07-01)

Myeloproliferative neoplasms and personalized medicine: the perfect match?
od: Jean-Jacques Kiladjian, i wsp.
Wydane: (2015-12-01)

Classification and personalized prognosis in myeloproliferative neoplasms
od: Grinfeld, J, i wsp.
Wydane: (2018)

Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study
od: Geenes, V, i wsp.
Wydane: (2014)

Myeloproliferative neoplasm stem cells
od: Mead, A, i wsp.
Wydane: (2017)

The Hematopoietic Niche in Myeloproliferative Neoplasms
od: Annette H. Schmitt-Graeff, i wsp.
Wydane: (2015-01-01)

Pathophysiology of thrombosis in myeloproliferative neoplasms
od: Raffaele Landolfi, i wsp.
Wydane: (2011-02-01)

Autoimmunity and the risk of myeloproliferative neoplasms
od: Sigurdur Y. Kristinsson, i wsp.
Wydane: (2010-07-01)

Interferons in the treatment of myeloproliferative neoplasms
od: Pankit Vachhani, i wsp.
Wydane: (2024-02-01)

Mutant Calreticulin in the Myeloproliferative Neoplasms
od: Daniel Prins, i wsp.
Wydane: (2020-02-01)

Neurological Findings in Myeloproliferative Neoplasms
od: Semra Paydas
Wydane: (2013-04-01)

Novel therapeutics in myeloproliferative neoplasms
od: Sangeetha Venugopal, i wsp.
Wydane: (2020-12-01)

Targeted therapies for myeloproliferative neoplasms
od: Bing Li, i wsp.
Wydane: (2019-07-01)

CALR Mutations in Myeloproliferative Neoplasms
od: Ken-Hong Lim
Wydane: (2014-06-01)

Molecular pathogenesis of the myeloproliferative neoplasms
od: Graeme Greenfield, i wsp.
Wydane: (2021-06-01)

UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN
od: Harrison, C, i wsp.
Wydane: (2019)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
od: Greenfield, G, i wsp.
Wydane: (2020)

Molecular basis of myelodysplastic/myeloproliferative neoplasms
od: Andreas Reiter, i wsp.
Wydane: (2009-12-01)

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
od: Cecilia P. Marin Oyarzún, i wsp.
Wydane: (2019-06-01)

Symptomatic burden amongst myeloproliferative neoplasm patients: mpn-10 prospective assessment in a portuguese cohort
od: Maria Sarmento, i wsp.
Wydane: (2021-12-01)

Heterogeneity in myeloproliferative neoplasms: causes and consequences
od: O'Sullivan, J, i wsp.
Wydane: (2018)

Mechanisms of disease transformation in myeloproliferative neoplasms
od: O'Sullivan, J
Wydane: (2022)

Epigenetics and mutations in chronic myeloproliferative neoplasms
od: Alessandro M. Vannucchi, i wsp.
Wydane: (2011-10-01)

Omalizumab alleviates pruritus in myeloproliferative neoplasms
od: Anna Ravn Landtblom, i wsp.
Wydane: (2023-01-01)

Blood cell activation in myeloproliferative neoplasms
od: Francisco Cervantes, i wsp.
Wydane: (2009-11-01)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
od: Stefan N. Constantinescu, i wsp.
Wydane: (2021-06-01)

Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?
od: Stephen E. Langabeer PhD, FRCPath
Wydane: (2023-06-01)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
od: Sylvie Hermouet, i wsp.
Wydane: (2023-05-01)

The Role of New Technologies in Myeloproliferative Neoplasms
od: Giuseppe A. Palumbo, i wsp.
Wydane: (2019-04-01)